In vivo eradication of MLL/ENL leukemia cells by NK cells in the absence of adaptive immunity

Leukemia

Volumn 28, Issue 6, 2014, Pages 1316-1325

  Nakata, J ^a   Nakano, K ^a   Okumura, A ^a   Mizutani, Y ^a   Kinoshita, H ^a   Iwai, M ^a   Hasegawa, K ^a   Morimoto, S ^a   Fujiki, F ^a   Tatsumi, N ^a   Nakajima, H ^a   Nakae, Y ^a   Nishida, S ^a   Tsuboi, A ^a   Oji, Y ^a   Oka, Y ^a,b   Sugiyama, H ^a   Kumanogoh, A ^a,b   Hosen, N ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

acute myeloid leukemia; MLL ENL; NK cell; tumor immunity

Indexed keywords

LIGAND; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; COMPLEMENTARY DNA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CELL TRANSPLANTATION; DISEASE COURSE; DISEASE ERADICATION; FEMALE; FUSION GENE; HEMATOPOIETIC STEM CELL; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; IN VIVO STUDY; LEUKEMIA CELL; LEUKEMIA CELL LINE; MLL ENL LEUKEMIA CELL LINE; MOUSE; MURINE LEUKEMIA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ENGRAFTMENT; TUMOR IMMUNITY; TUMOR REJECTION; UPREGULATION; WILD TYPE; CONTROLLED STUDY; ENGRAFTMENT; GENETIC TRANSFECTION; IMMUNE RESPONSE; MLL ENL LEUKEMIA CELL;

ADAPTIVE IMMUNITY; ANIMALS; APOPTOSIS; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; DNA-BINDING PROTEINS; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; ONCOGENE PROTEINS, FUSION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84902087253     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.374     Document Type: Article

References (45)

1. Burnet M. Cancer: A biological approach III. Viruses associated with neoplastic conditions. IV. Practical applications. BMJ 1957; 1: 841-847.
2. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-998. (Pubitemid 35363648)
3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570.
4. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482: 400-404.
5. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumourspecific antigens underlies cancer immunoediting. Nature 2012; 482: 405-409.
6. van den Broek ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996; 184: 1781-1790. (Pubitemid 26404469)
7. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001; 97: 192-197. (Pubitemid 32061260)
8. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168: 1356-1361. (Pubitemid 34094506)
9. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008; 28: 571-580.
10. Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008; 205: 2965-2973.
11. Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda S et al. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 2008; 205: 2959-2964.
12. Elboim M, Gazit R, Gur C, Ghadially H, Betser-Cohen G, Mandelboim O. Tumor immunoediting by NKp46. J Immunol 2010; 184: 5637-5644.
13. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885-13890. (Pubitemid 39298502)
14. Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997; 90: 2529-2534. (Pubitemid 27413460)
15. Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res 1999; 59: 2675-2681. (Pubitemid 29269115)
16. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102: 1389-1396. (Pubitemid 36988048)
17. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: Evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 2005; 105: 2066-2073. (Pubitemid 40731793)
18. Hilpert J, Grosse-Hovest L, Grunebach F, Buechele C, Nuebling T, Raum T et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: Implications for NKG2D-mediated NK cell responses. J Immunol 2012; 189: 1360-1371.
19. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell 1992; 71: 691-700.
20. Slany RK, Lavau C, Cleary ML. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol 1998; 18: 122-129. (Pubitemid 28021024)
21. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-Associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003; 17: 3029-3035. (Pubitemid 38040767)
22. Morita S, Kojima T, Kitamura T. Plat-E: An efficient and stable system for transient packaging of retroviruses. Gene Ther 2000; 7: 1063-1066. (Pubitemid 30398356)
23. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 1997; 16: 4226-4237. (Pubitemid 27298175)
24. Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006; 10: 257-268. (Pubitemid 44512188)
25. Hamby K, Trexler A, Pearson TC, Larsen CP, Rigby MR, Kean LS. NK cells rapidly reject allogeneic bone marrow in the spleen through a perforin-And Ly49D-dependent, but NKG2D-independent mechanism. Am J Transplant 2007; 7: 1884-1896. (Pubitemid 47037977)
26. Di Santo JP. Natural killer cell developmental pathways: A question of balance. Annu Rev Immunol 2006; 24: 257-286.
27. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol 2012; 12: 239-252.
28. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3: 781-790. (Pubitemid 37328656)
29. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: Role of natural killer cell receptors. Nat Rev Immunol 2009; 9: 568-580.
30. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331: 44-49.
31. Mooney JM, Klem J, Wulfing C, Mijares LA, Schwartzberg PL, Bennett M et al. The murine NK receptor 2B4 (CD244) exhibits inhibitory function independent of signaling lymphocytic activation molecule-Associated protein expression. J Immunol 2004; 173: 3953-3961. (Pubitemid 39280759)
32. Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D. Immune response to green fluorescent protein: Implications for gene therapy. Gene Ther 1999; 6: 1305-1312. (Pubitemid 29359025)
33. Rosenzweig M, Connole M, Glickman R, Yue SP, Noren B, DeMaria M et al. Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells. Blood 2001; 97: 1951-1959. (Pubitemid 32239073)
34. Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, Naldini L. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-Term expression of human antihemophilic factor IX in mice. Blood 2004; 103: 3700-3709. (Pubitemid 38596285)
35. Unni AM, Bondar T, Medzhitov R. Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance. Proc Natl Acad Sci USA 2008; 105: 1686-1691. (Pubitemid 351346575)
36. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001; 98: 11521-11526. (Pubitemid 32928761)
37. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165-171. (Pubitemid 32867877)
38. Ogasawara K, Benjamin J, Takaki R, Phillips JH, Lanier LL. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat Immunol 2005; 6: 938-945. (Pubitemid 43090449)
39. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002; 2: 850-861. (Pubitemid 37328903)
40. Zhang C, Zhang J, Tian Z. The regulatory effect of natural killer cells: Do 'NK-reg cells' exist? Cell Mol Immunol 2006; 3: 241-254.
41. Benson Jr. DM, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 2011; 118: 6387-6391.
42. Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A et al. A phase trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012; 120: 4317-4323.
43. Diermayr S, Himmelreich H, Durovic B, Mathys-Schneeberger A, Siegler U, Langenkamp U et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 2008; 111: 1428-1436. (Pubitemid 351213430)
44. Tang KF, He CX, Zeng GL, Wu J, Song GB, Shi YS et al. Induction of MHC class I-related chain B (MICB) by 5-Aza-2'-deoxycytidine. Biochem Biophys Res Commun 2008; 370: 578-583.
45. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009; 113: 3503-3511.